Related Experiment Video

Updated: May 21, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

The role of pharmacogenomics in metastatic renal cell carcinoma

Daniel Castellano1, Juan Antonio Virizuela, Josefina Cruz

  • 1Hospital Universitario 12 de Octubre, Madrid, Spain.

Cancer Metastasis Reviews
|June 23, 2012
PubMed

Insights

Pharmacogenomics can personalize cancer treatment by analyzing genetic variations that influence drug response. Genetic polymorphisms in patients with metastatic renal cell carcinoma (RCC) may predict outcomes with targeted therapies like TKIs and mTOR inhibitors.

Area of Science:

  • Pharmacogenomics and precision medicine in oncology.
  • Genetics and drug metabolism.
  • Biomarkers in cancer therapy.

Background:

  • Targeted therapies, including tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors, have improved outcomes for advanced or metastatic renal cell carcinoma (RCC).
  • Identifying biomarkers to predict patient response to these targeted drugs is crucial for optimizing treatment.
  • Genetic variations can significantly impact drug pharmacokinetics and pharmacodynamics.

Purpose of the Study:

  • To review single nucleotide polymorphisms (SNPs) associated with treatment outcomes and toxicity in metastatic RCC patients receiving targeted therapies.
  • To highlight key genes (IL8, FGFR2, VEGFA, FLT4, NR1I2) implicated in targeted drug response.
  • To provide recommendations for incorporating SNPs into personalized therapy strategies for RCC.

Main Methods:

  • Literature review of studies investigating genetic polymorphisms and their association with targeted therapy efficacy and safety in metastatic RCC.
  • Analysis of identified genetic polymorphisms in relation to progression-free survival and overall survival.
  • Synthesis of findings to inform future clinical trial design.

Main Results:

  • Several genetic polymorphisms have been linked to altered pharmacokinetics and/or pharmacodynamics of TKIs and mTOR inhibitors.
  • These polymorphisms are associated with improved progression-free survival and/or overall survival in metastatic RCC patients.
  • Specific genes such as IL8, FGFR2, VEGFA, FLT4, and NR1I2 are of significant interest.

Conclusions:

  • Genetic variations, specifically SNPs, play a role in the efficacy and toxicity of targeted therapies for metastatic RCC.
  • Pharmacogenomic approaches hold promise for personalizing treatment strategies in RCC.
  • Future clinical trials should aim to validate and integrate SNP analysis for guiding targeted therapy selection and dosing.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...